01 Shift toward Long-Acting Anti-VEGF TherapiesThe age-related macular degeneration market analysis shows a shift toward long-acting anti-VEGF therapies designed to extend treatment intervals and reduce the frequency of intravitreal injections. These therapies are being developed to provide sustained suppression of vascular endothelial growth factor activity in patients with neovascular age-related macular degeneration.
02 Use of Complement Inhibitor Therapies for Geographic AtrophyThe AMD market is witnessing growth in complement inhibitor therapies for geographic atrophy that target components of the complement pathway involved in retinal damage. These therapies are being developed to slow the progression of geographic atrophy and preserve retinal function for longer periods.
01 Supply chain disruptions are expected to have a moderate impact on the age-related macular degeneration market share due to dependence on biologic drugs, pharmaceutical ingredients, sterile injection supplies, ophthalmic products, and temperature-controlled pharmaceutical distribution networks. The market is expected to follow a stair-step recovery, as shortages of active pharmaceutical ingredients, manufacturing delays, sterile packaging constraints, and transportation disruptions can affect treatment availability in phases before pharmaceutical production and distribution capacity stabilize. The market is expected to grow at a CAGR of 8.90%, but supply chain constraints could approximately lower this by 1.0 percentage point, resulting in short-term growth of around 7.90%. As supply conditions normalize through improved availability of pharmaceutical ingredients and ophthalmic treatments, stable manufacturing capacity, reliable sterile supply chains, and smoother pharmaceutical distribution, age-related macular degeneration market growth is expected to gradually return to 8.90%.
01 The age-related macular degeneration market forecasts strategic investment activity driven by regenerative cell therapies, retinal implants, geographic atrophy treatments, advanced gene therapies, and the development of innovative vision restoration technologies.
02 Key Investment and Funding Activities in Age-Related Macular Degeneration Market, 2026CompanyValue (USD)DetailsGelMEDIXUSD 13 MillionIn February 2026, GelMEDIX completed a USD 13 million seed financing to advance GMX-101, a retinal pigment epithelial cell therapy for geographic atrophy, an advanced form of dry AMD.Science CorporationUSD 230 MillionIn 2026, Science Corporation raised USD 230 million to advance its Prima retinal implant and expand development of vision restoration technologies for late-stage AMD.
01 Demand for Less Frequent Injection Therapies and Expansion of Retinal Imaging Technologies Drives MarketThe demand for less frequent injection therapies is growing as patients and healthcare providers seek more convenient AMD treatment options. Longer acting therapies can extend the time between doses and reduce the burden of frequent eye injections. This can also help simplify long-term treatment management.The expansion of retinal imaging technologies is increasing demand for advanced tools that support early detection and monitoring of AMD. Technologies such as optical coherence tomography and retinal imaging systems help clinicians examine changes in retinal structure and disease progression. Better imaging can support more timely treatment decisions and regular monitoring.
01 Frequent Intravitreal Injection Requirements and Risk of Adverse Effects Associated with AMD Therapies Restraints Market ExpansionFrequent intravitreal injection requirements can create a treatment burden for patients with age-related macular degeneration. Anti-VEGF therapies often require repeated injections and regular follow-up visits to maintain disease control. This treatment burden can affect adherence and restrain market growth.The risk of adverse effects associated with AMD therapies can limit the use of certain treatment options. Intravitreal injections may be associated with complications such as eye inflammation, increased intraocular pressure, or infection. These safety concerns can influence treatment decisions and restrain market adoption.
01 Expansion of AMD Treatment in Specialty Eye Care and Monitoring Services Offers Growth OpportunitiesThe growing need for retinal care is creating opportunities for pharmaceutical companies and ophthalmology providers to serve eye hospitals, specialty clinics, and aging patients. Advanced therapies can help manage vision loss associated with different forms of AMD. Revenue can be generated through drug sales, treatment procedures, and specialist consultations, contributing to age-related macular degeneration market growth.The increasing need for early detection and continuous disease monitoring is creating opportunities for diagnostic providers and eye care centers. Retinal imaging and vision assessment services can support regular monitoring of disease progression and treatment response. Revenue can be generated through imaging procedures, diagnostic services, and recurring monitoring programs, supporting market growth.